<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01875224</url>
  </required_header>
  <id_info>
    <org_study_id>IM103-303</org_study_id>
    <nct_id>NCT01875224</nct_id>
  </id_info>
  <brief_title>Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression</brief_title>
  <official_title>Open-Label, Randomized Comparison of NODAT in Renal Transplant Patients Receiving a Nulojix (Belatacept) Regimen Versus Standard Therapy Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if belatacept is an appropriate alternative
      immunosuppressive medication (reducing the immune system's effect) when a kidney transplant
      patient develops new onset diabetes after transplant (NODAT). Patients who are diagnosed with
      NODAT will be approached with the opportunity to participate in this study. If they agree to
      participate, they will be randomized one-to-one (like a coin flip) to the study arm
      (belatacept) or the control arm (their current medication regimen). If a patient is
      randomized to the study arm, they will be tapered off of their current regimen when they have
      started receiving their monthly belatacept infusions. The control arm will mean the patient
      will continue their current, standard of care medications, but following the tacrolimus
      trough levels indicated within the study protocol. Different laboratory tests (i.e. fasting
      blood glucose) will be measured during the study to monitor the progression of NODAT in all
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased insulin sensitivity</measure>
    <time_frame>12 months</time_frame>
    <description>Increase in insulin sensitivity (HOMA-S) as calculated below:
FIRI = fasting plasma insulin level
FPG = fasting plasma glucose level
HOMA-S (insulin sensitivity) is calculated as 22.5 / (FIRI * FPG)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decreased insulin resistance</measure>
    <time_frame>12 months</time_frame>
    <description>Decreased insulin resistance (HOMA-IR) as measured below:
FIRI = fasting plasma insulin level
FPG = fasting plasma glucose level
HOMA IR (insulin resistance) is calculated as (FIRI * FPG) / 22.5</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>New Onset Diabetes After Transplant</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Belatacept and CellCept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus and CellCept</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus and CellCept taken twice daily based on patient response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <arm_group_label>Belatacept and CellCept</arm_group_label>
    <other_name>Nulojix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Standard administration of tacrolimus</description>
    <arm_group_label>Tacrolimus and CellCept</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be given by patient.

          -  Adult patients between age 18 and 65

          -  Thymoglobulin induction at the time of transplant

          -  Patient must be Epstein-Barr Virus seropositive

        Exclusion Criteria:

          -  Patient who received an blood type incompatible transplant, or with T-cell or B-cell
             positive crossmatch

          -  Patients with Hepatitis B, Hepatitis C, HIV or a clinically significant systemic
             infection within 30 days prior to transplant

          -  History of stroke, severe cardiac disease or cardiac failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce Kaplan, MD</last_name>
    <phone>520-626-6371</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rochelle Byrne, RN</last_name>
    <phone>520-626-9603</phone>
    <email>rbyrne@deptofmed.arizona.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rochelle Byrne, RN</last_name>
      <phone>520-626-9603</phone>
      <email>rbyrne@deptofmed.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Bruce Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Bruce Kaplan</investigator_full_name>
    <investigator_title>Chief of Abdominal Transplantation</investigator_title>
  </responsible_party>
  <keyword>kidney transplant</keyword>
  <keyword>diabetes after transplant</keyword>
  <keyword>belatacept</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

